Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis. (Q38033192)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Mahmoud Ghannoum

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

9 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

1549-1562

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22876754%20AND%20SRC:MED&resulttype=core&format=json

Achilles foot-screening project: background, objectives and design

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Onychomycosis in Denmark: prevalence of fungal nail infection in general practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Drug interactions of the newer oral antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Onychomycosis: diagnosis and definition of cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Effect of onychomycosis on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Risk factors associated with onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Patients at risk of onychomycosis--risk factor identification and active prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Oral treatments for toenail onychomycosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Guidelines for treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Treatment options--development of consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Clinical practice. Fungal nail disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Terbinafine-induced hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Serious adverse events reporting on systemic terbinafine: a Danish register-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Onychomycosis in clinical practice: factors contributing to recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Effect of polyethylene glycols on the trans-ungual delivery of terbinafine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Improved risk-benefit ratio for topical triamcinolone acetonide in TransfersomeR in comparison with equipotent cream and ointment: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Transfersomes for transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Activity of TDT 067 (terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

New fungal nail infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Non-dermatophyte onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Short term treatment of dermatophyte onychomycosis with terbinafine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

A randomized treatment duration-finding study of terbinafine in onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315

Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2012.711315